Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | PKM | P14618 | 3/20 | 0.64 |
| ▸ | HTT | P42858 | 2/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | RAB9A | P51151 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | EBP | Q15125 | 1/20 | 0.57 |
| ▸ | DHCR7 | Q9UBM7 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28847667 | 0.90 | PKM (0.57) | ALDH1A1PKMHTTPOLBKDM4E | |
| SCHEMBL28882522 | 0.84 | ALDH1A1 (0.66) | ALDH1A1PKMHTTPOLBKDM4E | |
| SCHEMBL266466 | 0.84 | MEN1 (0.77) | ALDH1A1PKMHTTPOLBKDM4E | |
| SCHEMBL699639 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 | |
| SCHEMBL4537086 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 | |
| SCHEMBL8203532 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 | |
| SCHEMBL3303527 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 | |
| SCHEMBL565301 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 | |
| SCHEMBL10724066 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 | |
| SCHEMBL3971438 | 0.83 | PKM (0.88) | ALDH1A1PKMHTTPOLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765788-B2 | Tricyclic inhibitors of hydroxysteroid dehydrogenases | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2010-11-04 | — | — | US | disclosed |
| EP-2162439-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | Amgen Inc. (US) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008156601-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156601-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280073-A1 | TRICYCLIC INHIBITORS OF HYDROXYSTEROID DEHYDROGENASES | HSD11B1, HSD3B1, HSD17B1 | ALDH1A1 185/4885PKM 843/4885HTT 1886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.